Crazyjogger, ICU occupancy in greater São Paul
Post# of 148290
(Total Views: 583)
Posted On: 01/26/2022 6:23:45 AM
Crazyjogger,
ICU occupancy in greater São Paulo (location of more than half of Leronlimab trials) continues to climb by 2% daily. 72% ICU occupancy, 77% total bed occupancy.
https://www.seade.gov.br/coronavirus/
Admissions of course lag infections, which have nearly doubled (+91%) over the last week.
https://www.worldometers.info/coronavirus/wee...ekly_table
Interim analysis of critical covid trial at 51 patients at 27 days (noted in 10q)
“ In December 2021, Brazil’s ANVISA agreed to modify the Phase 3 trial for critically ill COVID-19 patients to require a total patient enrollment of 126 patients instead of the previously approved 316 patients and allow for interim efficacy analysis after 51 patients have been treated for 27 days.”
Bad times nearly all around for Covid. Record highs in daily cases today in Russia, Poland, Czechia, Austria and Japan (so far).
As always, Cytodyn needs to show the data. Regulatory approvals will follow.
ICU occupancy in greater São Paulo (location of more than half of Leronlimab trials) continues to climb by 2% daily. 72% ICU occupancy, 77% total bed occupancy.
https://www.seade.gov.br/coronavirus/
Admissions of course lag infections, which have nearly doubled (+91%) over the last week.
https://www.worldometers.info/coronavirus/wee...ekly_table
Interim analysis of critical covid trial at 51 patients at 27 days (noted in 10q)
“ In December 2021, Brazil’s ANVISA agreed to modify the Phase 3 trial for critically ill COVID-19 patients to require a total patient enrollment of 126 patients instead of the previously approved 316 patients and allow for interim efficacy analysis after 51 patients have been treated for 27 days.”
Bad times nearly all around for Covid. Record highs in daily cases today in Russia, Poland, Czechia, Austria and Japan (so far).
As always, Cytodyn needs to show the data. Regulatory approvals will follow.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼